<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Medical Companies &#187; United Kingdom</title>
	<atom:link href="http://www.medicalmagazine.net/medical/united-kingdom/feed" rel="self" type="application/rss+xml" />
	<link>http://www.medicalmagazine.net</link>
	<description></description>
	<lastBuildDate>Sun, 25 Jul 2010 22:45:54 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.0</generator>
		<item>
		<title>Senetek PLC</title>
		<link>http://www.medicalmagazine.net/senetek-plc.html</link>
		<comments>http://www.medicalmagazine.net/senetek-plc.html#comments</comments>
		<pubDate>Sun, 06 Dec 2009 05:55:15 +0000</pubDate>
		<dc:creator>medical products</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[United Kingdom]]></category>

		<guid isPermaLink="false">http://localhost/wp/en/medicalmagazine-net/?p=2553</guid>
		<description><![CDATA[Industry: Pharmaceuticals, Biotechnology ITEM 1BUSINESS Overview Senetek PLC, together with its subsidiaries (the Company which may be referred to as Senetek, we, us, or our), is a public limited company organized under the laws of England in 1983 (registration number 1759068). Senetek has four wholly-owned subsidiaries, Senetek Drug Delivery Technologies Inc. (SSDT), Senetek Asia Limited [...]]]></description>
			<content:encoded><![CDATA[<p>Industry: Pharmaceuticals, Biotechnology<br />
ITEM 1BUSINESS Overview Senetek PLC, together with its subsidiaries (the Company which may be referred to as Senetek, we, us, or our), is a public limited company organized under the laws of England in 1983 (registration number 1759068). Senetek has four wholly-owned subsidiaries, Senetek Drug Delivery Technologies Inc. (SSDT), Senetek Asia Limited (HK) and Senetek Denmark ApS, corporations formed by &#8230; ( www.senetekplc.com )</p>
<p>Senetek PLC<br />
620 Airpark Rd<br />
LONDON SW1E 5HW<br />
United Kingdom</p>
]]></content:encoded>
			<wfw:commentRss>http://www.medicalmagazine.net/senetek-plc.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Amersham plc</title>
		<link>http://www.medicalmagazine.net/amersham-plc.html</link>
		<comments>http://www.medicalmagazine.net/amersham-plc.html#comments</comments>
		<pubDate>Sun, 06 Dec 2009 05:45:03 +0000</pubDate>
		<dc:creator>medical products</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[United Kingdom]]></category>

		<guid isPermaLink="false">http://localhost/wp/en/medicalmagazine-net/?p=2537</guid>
		<description><![CDATA[Industry: Pharmaceuticals, Biotechnology Amersham is a world leader in medical diagnostics and in life sciences. We employ 9,500 people around the world. Our shares are traded on the London, New York and Oslo stock exchanges (AHM), and we are listed on the FTSE Index of Britain&#8217;s 100 largest companies. Our company was formed in 1997 [...]]]></description>
			<content:encoded><![CDATA[<p>Industry: Pharmaceuticals, Biotechnology<br />
Amersham is a world leader in medical diagnostics and in life sciences. We employ 9,500 people around the world. Our shares are traded on the London, New York and Oslo stock exchanges (AHM), and we are listed on the FTSE Index of Britain&#8217;s 100 largest companies. Our company was formed in 1997 from the businesses of Amersham International (UK), Pharmacia Biotech (Sweden) and Nycomed (Norway). In 2001 the company changed its name to Amersham plc and our businesses became Amersham Biosciences and Amersham Health. Together we combine skills in understanding genetic predisposition and the molecular basis of disease, with those for screening for ( www.amersham.com )</p>
<p>Amersham plc<br />
Amersham Place<br />
Little Chalfont, Buckinghamshire HP7 9NA<br />
United Kingdom</p>
<p>Tel: +44 1494 544000<br />
Fax: +44 1494 542266</p>
]]></content:encoded>
			<wfw:commentRss>http://www.medicalmagazine.net/amersham-plc.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Oxford BioMedica plc</title>
		<link>http://www.medicalmagazine.net/oxford-biomedica-plc.html</link>
		<comments>http://www.medicalmagazine.net/oxford-biomedica-plc.html#comments</comments>
		<pubDate>Sun, 06 Dec 2009 05:42:32 +0000</pubDate>
		<dc:creator>medical products</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[United Kingdom]]></category>

		<guid isPermaLink="false">http://localhost/wp/en/medicalmagazine-net/?p=2533</guid>
		<description><![CDATA[Industry: Pharmaceuticals, Biotechnology Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the development of novel gene-based therapeutics with a focus on oncology and neurotherapy. The Company was established in 1995 as a spin out from Oxford University, and is listed on the London Stock Exchange. Oxford BioMedica has core expertise in gene delivery, [...]]]></description>
			<content:encoded><![CDATA[<p>Industry: Pharmaceuticals, Biotechnology<br />
Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the development of novel gene-based therapeutics with a focus on oncology and neurotherapy. The Company was established in 1995 as a spin out from Oxford University, and is listed on the London Stock Exchange. Oxford BioMedica has core expertise in gene delivery, as well as in-house clinical, regulatory and manufacturing know-how. In oncology, the pipeline includes two clinical candidates and a preclinical targeted antibody therapy, which is being developed in collaboration with Wyeth. The Company has started Phase III development of its lead cancer immunotherapy product, TroVax, in renal cancer and has an ongoing Phase II programme in various cancer settings including renal, colorectal and prostate ( www.oxfordbiomedica.co.uk )</p>
<p>Oxford BioMedica plc<br />
The Medawar Centre<br />
Oxford, OXON Ox4 4ga<br />
United Kingdom</p>
]]></content:encoded>
			<wfw:commentRss>http://www.medicalmagazine.net/oxford-biomedica-plc.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Thiakis Limited</title>
		<link>http://www.medicalmagazine.net/thiakis-limited.html</link>
		<comments>http://www.medicalmagazine.net/thiakis-limited.html#comments</comments>
		<pubDate>Sun, 06 Dec 2009 05:25:29 +0000</pubDate>
		<dc:creator>medical products</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[United Kingdom]]></category>

		<guid isPermaLink="false">http://localhost/wp/en/medicalmagazine-net/?p=2507</guid>
		<description><![CDATA[Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology Thiakis is a privately owned biopharmaceutical company founded in 2004; focused on the development of novel therapeutic approaches for the treatment of obesity and other metabolic diseases. ( www.thiakis.com ) Thiakis Limited Bessemer Building (RSM) Prince Consort Road London SW7 2BP United Kingdom Tel: +44 207 594 1059 Fax: +44 [...]]]></description>
			<content:encoded><![CDATA[<p>Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology<br />
Thiakis is a privately owned biopharmaceutical company founded in 2004; focused on the development of novel therapeutic approaches for the treatment of obesity and other metabolic diseases. ( www.thiakis.com )</p>
<p>Thiakis Limited<br />
Bessemer Building (RSM) Prince Consort Road<br />
London SW7 2BP<br />
United Kingdom</p>
<p>Tel: +44 207 594 1059<br />
Fax: +44 207 594 1070</p>
]]></content:encoded>
			<wfw:commentRss>http://www.medicalmagazine.net/thiakis-limited.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>GeneMedix plc</title>
		<link>http://www.medicalmagazine.net/genemedix-plc.html</link>
		<comments>http://www.medicalmagazine.net/genemedix-plc.html#comments</comments>
		<pubDate>Sun, 06 Dec 2009 02:59:02 +0000</pubDate>
		<dc:creator>medical products</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[United Kingdom]]></category>

		<guid isPermaLink="false">http://localhost/wp/en/medicalmagazine-net/?p=2463</guid>
		<description><![CDATA[Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology GeneMedix is a UK based, globally focused biopharmaceutical company, specialising in the development and manufacture of cost effective treatments for some of the world&#8217;s most serious diseases. The strategy for GeneMedix continues to focus on commercialising a range of high quality, therapeutic proteins and initially launching in markets where patents [...]]]></description>
			<content:encoded><![CDATA[<p>Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology<br />
GeneMedix is a UK based, globally focused biopharmaceutical company, specialising in the development and manufacture of cost effective treatments for some of the world&#8217;s most serious diseases. The strategy for GeneMedix continues to focus on commercialising a range of high quality, therapeutic proteins and initially launching in markets where patents have never existed, or have expired, in order to make such products available to a wider number of patients globally. ( www.genemedix.com )</p>
<p>GeneMedix plc<br />
Rosalind Franklin House Fordham Road<br />
Newmarket, CB8 7XN<br />
United Kingdom</p>
<p>Tel: +44 1638 663320</p>
]]></content:encoded>
			<wfw:commentRss>http://www.medicalmagazine.net/genemedix-plc.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharmexa</title>
		<link>http://www.medicalmagazine.net/pharmexa.html</link>
		<comments>http://www.medicalmagazine.net/pharmexa.html#comments</comments>
		<pubDate>Sun, 06 Dec 2009 02:32:24 +0000</pubDate>
		<dc:creator>medical products</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[United Kingdom]]></category>

		<guid isPermaLink="false">http://localhost/wp/en/medicalmagazine-net/?p=2445</guid>
		<description><![CDATA[Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology Pharmexa is a leading biotech company in the field of active immunotherapy and vaccines for the treatment of cancer, serious chronic and infectious diseases. The company has been listed on the Copenhagen Stock Exchange since 2000. The Pharmexa group consists of GemVax AS, a Norwegian subsidiary, developing peptide vaccines for [...]]]></description>
			<content:encoded><![CDATA[<p>Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology<br />
Pharmexa is a leading biotech company in the field of active immunotherapy and vaccines for the treatment of cancer, serious chronic and infectious diseases. The company has been listed on the Copenhagen Stock Exchange since 2000. The Pharmexa group consists of GemVax AS, a Norwegian subsidiary, developing peptide vaccines for cancer and Pharmexa-Epimmune, a US subsidiary, focusing on T cell epitope-based vaccines for cancer and infectious diseases. ( www.pharmexa.com )</p>
<p>Pharmexa<br />
Piper Jaffray Ltd. &#8211; Dr. Richard Parks &#038; Dr. Sally Bennett 18 King William Street<br />
London EC4N 7US<br />
United Kingdom</p>
<p>Tel: +45 8922 2864</p>
]]></content:encoded>
			<wfw:commentRss>http://www.medicalmagazine.net/pharmexa.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Syntopix Group plc</title>
		<link>http://www.medicalmagazine.net/syntopix-group-plc-2.html</link>
		<comments>http://www.medicalmagazine.net/syntopix-group-plc-2.html#comments</comments>
		<pubDate>Sun, 06 Dec 2009 02:28:05 +0000</pubDate>
		<dc:creator>medical products</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[United Kingdom]]></category>

		<guid isPermaLink="false">http://localhost/wp/en/medicalmagazine-net/?p=2429</guid>
		<description><![CDATA[Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology Syntopix Group plc is a drug development company focused on prescription and over-the counter products for the treatment of common inflammatory skin conditions. Our vision is to become a world-class company providing clinical solutions for important dermatological diseases. This will be achieved by creating a continuous pipeline of novel products [...]]]></description>
			<content:encoded><![CDATA[<p>Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology<br />
Syntopix Group plc is a drug development company focused on prescription and over-the counter products for the treatment of common inflammatory skin conditions. Our vision is to become a world-class company providing clinical solutions for important dermatological diseases. This will be achieved by creating a continuous pipeline of novel products for the topical treatment and prevention of dermatological conditions, principally acne and staphylococcal infections including MRSA. The Syntopix strategy has been designed to reduce the risks and costs associated with drug discovery and development. We concentrate on change of use and combinations of known compounds with well-documented pharmacology and toxicity profiles that are already established as safe for human ( www.syntopix.com )</p>
<p>Syntopix Group plc<br />
Leeds Innovation Building 103 Clarendon Road<br />
Leeds, LS2 9DF<br />
United Kingdom</p>
<p>Tel: +44 8451 259204<br />
Fax: +44 8451 259205</p>
]]></content:encoded>
			<wfw:commentRss>http://www.medicalmagazine.net/syntopix-group-plc-2.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Syntopix Group plc</title>
		<link>http://www.medicalmagazine.net/syntopix-group-plc.html</link>
		<comments>http://www.medicalmagazine.net/syntopix-group-plc.html#comments</comments>
		<pubDate>Sun, 06 Dec 2009 02:21:59 +0000</pubDate>
		<dc:creator>medical products</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[United Kingdom]]></category>

		<guid isPermaLink="false">http://localhost/wp/en/medicalmagazine-net/?p=2427</guid>
		<description><![CDATA[Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology Syntopix Group plc is a drug development company focused on prescription and over-the counter products for the treatment of common inflammatory skin conditions. Our vision is to become a world-class company providing clinical solutions for important dermatological diseases. This will be achieved by creating a continuous pipeline of novel products [...]]]></description>
			<content:encoded><![CDATA[<p>Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology<br />
Syntopix Group plc is a drug development company focused on prescription and over-the counter products for the treatment of common inflammatory skin conditions. Our vision is to become a world-class company providing clinical solutions for important dermatological diseases. This will be achieved by creating a continuous pipeline of novel products for the topical treatment and prevention of dermatological conditions, principally acne and staphylococcal infections including MRSA. The Syntopix strategy has been designed to reduce the risks and costs associated with drug discovery and development. We concentrate on change of use and combinations of known compounds with well-documented pharmacology and toxicity profiles that are already established as safe for human ( www.syntopix.com )</p>
<p>Syntopix Group plc<br />
Leeds Innovation Building 103 Clarendon Road<br />
Leeds, LS2 9DF<br />
United Kingdom</p>
<p>Tel: +44 8451 259204<br />
Fax: +44 8451 259205</p>
]]></content:encoded>
			<wfw:commentRss>http://www.medicalmagazine.net/syntopix-group-plc.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Hunter-Fleming Ltd</title>
		<link>http://www.medicalmagazine.net/hunter-fleming-ltd.html</link>
		<comments>http://www.medicalmagazine.net/hunter-fleming-ltd.html#comments</comments>
		<pubDate>Sun, 06 Dec 2009 02:19:15 +0000</pubDate>
		<dc:creator>medical products</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[United Kingdom]]></category>

		<guid isPermaLink="false">http://localhost/wp/en/medicalmagazine-net/?p=2421</guid>
		<description><![CDATA[Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology Hunter-Fleming is a biopharmaceutical company developing new medicines to treat neurological and cardiovascular disorders. The company focus is on unmet patient needs in dementias such as Alzheimer&#8217;s disease, as well as other important conditions such as neuropathic pain, head and spinal cord injuries and myocardial infarction. ( www.hunter-fleming.com ) Hunter-Fleming [...]]]></description>
			<content:encoded><![CDATA[<p>Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology<br />
Hunter-Fleming is a biopharmaceutical company developing new medicines to treat neurological and cardiovascular disorders. The company focus is on unmet patient needs in dementias such as Alzheimer&#8217;s disease, as well as other important conditions such as neuropathic pain, head and spinal cord injuries and myocardial infarction. ( www.hunter-fleming.com )</p>
<p>Hunter-Fleming Ltd<br />
Regus House 1 Friary Temple Quay<br />
Bristol BS1 6EA<br />
United Kingdom</p>
<p>Tel: +44 117 900 8265<br />
Fax: +44 117 900 8424</p>
]]></content:encoded>
			<wfw:commentRss>http://www.medicalmagazine.net/hunter-fleming-ltd.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Curidium Limited</title>
		<link>http://www.medicalmagazine.net/curidium-limited.html</link>
		<comments>http://www.medicalmagazine.net/curidium-limited.html#comments</comments>
		<pubDate>Sun, 06 Dec 2009 02:16:13 +0000</pubDate>
		<dc:creator>medical products</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[United Kingdom]]></category>

		<guid isPermaLink="false">http://localhost/wp/en/medicalmagazine-net/?p=2407</guid>
		<description><![CDATA[Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology Curidium is a drug discovery and development company focused on identifying targeted medicines to treat patients more effectively. Curidium has developed a novel and proprietary technology, Homomatrix®, to untangle the underlying mechanisms of human diseases. Curidium&#8217;s technology identifies different patient subpopulations each having a distinct disease mechanism. This enables the [...]]]></description>
			<content:encoded><![CDATA[<p>Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology<br />
Curidium is a drug discovery and development company focused on identifying targeted medicines to treat patients more effectively. Curidium has developed a novel and proprietary technology, Homomatrix®, to untangle the underlying mechanisms of human diseases. Curidium&#8217;s technology identifies different patient subpopulations each having a distinct disease mechanism. This enables the generation of new diagnostic tools and medicines designed for a subgroup of patients and potentially offering improved safety and effectiveness. Curidium is initially applying its core technology to diseases of the Central Nervous System. Curidium listed on the AIM of the London Stock Exchange on 6 July 2006 and trades under the symbol CUR. Recent News: 15 Dec 2006 ( www.curidium.com )</p>
<p>Curidium Limited<br />
Hamilton House Mabledon Place<br />
London WC1H 9BB<br />
United Kingdom</p>
<p>Tel: +44 20 7554 8790</p>
]]></content:encoded>
			<wfw:commentRss>http://www.medicalmagazine.net/curidium-limited.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
